TP53 and bladder transitional cell carcinoma: As a result, we found that patients with a mutation in TP53 and RB1, which is often mutated in a later stage of BLCA (MIBC) and recognized as a key element in BLCA development, exhibited higher ATGRS risk scores compared with the ATGRS low‐risk group (Figure 5A,B and E).